Uses a mix of both quantitative and qualitative methods to help policy makers identify sources of innovation in the knowledge-based economy and to best leverage these sources for regional economic growth.
The reactive approach to emerging infectious disease should be augmented with an anticipatory model that accounts for the dramatic changes occurring through globalization, greater interactions between human and zoonotic populations, and changes to the environment and climate patterns.
This paper reflects on the variety and evolution of population-scale genome-sequencing initiatives, examining their diverse aims, activities, management and governance approaches, impacts, and policy and research implications.
This report presents a bibliometric analysis of biomedical and health research in England, 2004-2013. It is intended to support the shortlisting and selection of the National Institute for Health Research Biomedical Research Centres in England.
This report summarises the key findings of a bibliometric analysis of researchers affiliated with the Cambridge Neuroscience Strategic Research Initiative at the University of Cambridge with a view to informing the future direction of the initiative.
Examines the relationship between federal funding and research productivity, as revealed through publications and citations, for a sample of academic researchers with sustainable energy technology interests.
RAND Health Advisory Services develops meaningful, innovative, and practical solutions for companies and associations that navigate the evolving health-care environment—particularly the transition from “pay-for-volume” to “pay-for-value.”
Open innovation is often suggested as a solution to enhance productivity in under-performing areas of research. Now, the strengths and weaknesses of a new open innovation model in drug discovery have been evaluated.
The Structural Genomics Consortium (SGC) is a not-for-profit, public-private partnership formed to support drug-discovery through pre-competitive structural biology research. The SGC has commissioned RAND Europe and Canada's Institute on Governance to provide an evaluation of its unique, open-access model, to understand the nature and diversity of its benefits for partnering organisations as well as for the wider research community.
An independent evaluation of the Structural Genomics Consortium (SGC) examined the strengths and weaknesses of its efforts to support drug discovery efforts through a unique, open access model of public-private collaboration.
This report summarises the results of an independent evaluation of the Structural Genomics Consortium, an open access model of public-private collaboration, conducted by RAND Europe with the Institute on Governance.
Dr. Gill Samuels CBE joined the RAND Europe Council of Advisors during its meeting in January. She is a physiologist and neuropharmacologist by training and was Director of Cardiovascular Biology at Pfizer, contributing to the discovery and development of a number of medicines.
This paper evaluates how changes in US National Institutes of Health (NIH) funding levels affected US universities' total biomedical R&D efforts, over a period of dramatic change in the federal funding environment.